Anthropic Enters Drug Discovery Race with Claude Science Launch

Anthropic has made a bold move into the pharmaceutical world. The AI company is launching an internal drug discovery program as part of a broader effort to develop artificial intelligence tools for drugmakers. At an event for pharmaceutical executives, biotech founders, and researchers, Anthropic announced Claude Science, a major new product intended to support scientific research. Like Claude Code, Claude Science can autonomously carry out meaningful work when given concise, high-level instructions, with access to tools useful for computational biology and drug development. The platform integrates over 60 scientific databases and computation tools in a single workplace. Anthropic's Head of Life Sciences Eric Kauderer-Abrams said the company plans to prioritize discovering drugs for "neglected" diseases outside the scope of traditional pharmaceutical companies. Anthropic has already inked a collaboration with Bristol Myers Squibb to roll out Claude to over 30,000 employees.

‍